Hepagard Granules contain L-Ornithine L-Aspartate (3 gm), a hepatoprotective agent primarily used in the management of hepatic encephalopathy and other liver disorders associated with hyperammonemia. The active compound facilitates the detoxification of ammonia by enhancing the urea cycle and glutamine synthesis in the liver, thereby reducing elevated blood ammonia levels commonly observed in patients with liver cirrhosis, acute liver failure, or chronic liver disease. Hepagard Granules are indicated as an adjunctive therapy to improve neuropsychiatric symptoms related to hepatic encephalopathy and to support liver function. The granule formulation allows for easy administration, especially in patients with swallowing difficulties. Hepagard is generally well tolerated, with minimal adverse effects; however, patients should be monitored for any hypersensitivity reactions or gastrointestinal disturbances. It is contraindicated in individuals with known hypersensitivity to L-Ornithine L-Aspartate or any excipients in the formulation. Dosage and duration of therapy should be individualized based on clinical response and severity of the condition, under the supervision of a healthcare professional. Hepagard Granules should be used as part of a comprehensive treatment plan, including dietary management and other supportive measures for optimal patient outcomes.